Identification of Molecular Markers of Clozapine Action in Ketamine-Induced Cognitive Impairment: A GPCR Signaling PathwayFinder Study
Background: Cognitive disorders associated with schizophrenia are closely linked to prefrontal cortex (PFC) dysfunction. Administration of the non-competitive NMDA receptor antagonist ketamine (KET) induces cognitive impairment in animals, producing effects similar to those observed in schizophrenic...
Saved in:
Main Authors: | Agata Korlatowicz, Maciej Kuśmider, Marta Szlachta, Paulina Pabian, Joanna Solich, Marta Dziedzicka-Wasylewska, Agata Faron-Górecka |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/bdffb22fddcf4d70b777e83dfe97f5e5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A survey of personnel and services offered in 32 outpatient US clozapine clinics
by: Robert O. Cotes, et al.
Published: (2021) -
Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
by: Fitri Fareez Ramli, et al.
Published: (2021) -
Effects of somatic treatments on suicidal ideation and completed suicides
by: Elise M Hawkins, et al.
Published: (2021) -
Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia
by: Amina Aissa, et al.
Published: (2022) -
Clozapine As Transformative Treatment In Bipolar Patients
by: Wilkowska A, et al.
Published: (2019)